stockportfolio.pro
Stocks / RARE vs VERA
RARE vs VERA
Ultragenyx Pharmaceutical Inc. and Vera Therapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Ultragenyx Pharmaceutical Inc. (RARE) | Vera Therapeutics, Inc. (VERA) | |
|---|---|---|
| Market cap | $2.3B | $2.4B |
| Revenue (latest FY) | $673.00M | $0 |
| Net income (latest FY) | $-575.00M | $-299.62M |
| Revenue growth (5y CAGR) | 19.9% | — |
| Net margin | -85.4% | — |
| Return on equity | 718.8% | -49.6% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open RARE — free Open VERA — freeFrequently asked questions
Which is bigger, RARE or VERA?
Vera Therapeutics, Inc. is larger by market capitalization — $2.4B versus $2.3B.
Which grows faster, RARE or VERA?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.